E2F-1, a transcription factor by discovery, is thought to play a crucial role in regulating G 1 /S cell cycle progression. Its activity is modulated by complex formation with the retinoblastoma protein and related proteins. Overexpression of E2F-1 has been shown to induce apoptosis in quiescent fibroblasts. We constructed a recombinant E2F-1 adenovirus to test whether an overexpression of E2F-1 in head and neck squamous cell carcinoma cell lines would also induce apoptosis. Two cell lines, Tu-138 and Tu-167, were chosen for use in this study. Both cell lines harbor p53 mutations but express different levels of the retinoblastoma protein. Upon E2F-1 adenovirus infection, both cell lines expressed elevated levels of E2F-1 protein and then activated a pRb-chloramphenicol acetyltransferase reporter construct containing an E2F-1 binding motif. In vitro growth assay demonstrated that growth suppression by the E2F-1 protein was effective on both cell lines. Results from DNA fragmentation and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling analyses indicated apoptosis induction in cells infected with AdCMV-E2F-1. Moreover, ex vivo experiments in nude mice showed total suppression of tumor growth at sites that received cells infected AdCMV-E2F-1. An in vivo analysis of apoptosis using in situ end-labeling further demonstrated the induction of apoptosis by AdCMV-E2F-1 in tumor-bearing animals. These data indicate that overexpression of E2F-1 via an adenoviral vector suppresses in vitro and in vivo growth of head and neck squamous carcinoma cell lines through induction of apoptosis.
O ver the past 30 years, despite advances in surgical and radiotherapy techniques and the institution of contemporary, combined-modality therapy, the overall survival rates for patients with squamous cell carcinoma of the head and neck (SCCHN) patients have remained unchanged. 1 Since its introduction in 1990, gene therapy has undergone a tremendous evolution, including the development of vehicles for the delivery of certain genes of interest. 2 The ultimate goal in treating cancer patients is to eradicate cancer cells. Immunomodulation is one of many strategies in cancer gene therapy in which the immune response of the host to tumor cells is augmented by the expression of various cytokines. 3 The introduction of a suicide gene such as herpes simplex virus thymidine kinase into cancer cells is another approach to eliminating tumor cells. However, additional ganciclovir administration following the transduction of thymidine kinase into tumor cells is necessary for the success of such a strategy. 4 Recently, the use of tumor suppressor gene such as p53 in cancer gene therapy has gained some attention. Apoptosis induction via a p53-dependent pathway has been well documented in various type of cancers, including colon cancer, 5 osteosarcoma, 6 lung cancer, 7 and head and neck cancer. 8 Suppression of tumor formation in animals has been noted as a consequence of apoptosis induction by overexpression of p53 protein. 8 Several genes have been implicated in the apoptotic pathway in human cancers, including bcl-x, 9 Bax, 10 and Bad. E2F-1 belongs to a family of factors that bind to retinoblastoma (Rb) protein. 12 The ability of E2F-1 to associate with another E2F-like protein, DP-1, confers a synergistic effect on transcriptional activity. 13 Moreover, E2F-1 operates under the tight control of cell-cycle machinery, with its peak expression at the G 1 /S boundary.
14 Several recent studies have indicated that E2F-1 may have functions besides promoting entry into the S phase. One of these functions may involve the regulation of apoptosis. The unregulated expression of E2F-1 in quiescent fibroblasts can trigger apoptosis. 15 In view of such an observation, we sought to investigate whether an overexpression of E2F-1 in proliferating cancer cells could also lead to apoptosis. Using adenoviral-mediated gene transfer, we demonstrated that an overexpression of E2F-1 induced the apoptosis of SCCHN cell lines and further inhibited tumor formation in animals.
MATERIALS AND METHODS

Cell lines and culture conditions
The human SCCHN cell lines Tu-138 and Tu-167 were established in the Department of Head and Neck Surgery at The University of Texas M.D. Anderson Cancer Center. Tu-138, Tu-167, and 686LN were developed by the primary explant technique as described previously 16 and were cytokeratinpositive. These cells were grown in Dulbecco's modified Eagle's medium (DMEM)/Ham's F12 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) with penicillin/streptomycin. ML-1, a human myeloid leukemia cell line (kindly provided by Dr. Ed Harlow, Massachusetts General Hospital, Charlestown, Mass), was grown in DMEM supplemented with 10% heat-inactivated FBS.
Cloning and sequencing of E2F-1 cDNA
The extraction of mRNA from the ML-1 cell line was performed using the QIAgene mRNA isolation kit (Qiagen, Valencia, Calif). First-strand cDNA was synthesized using superscript II ribonuclease (RNase) H Ϫ reverse transcriptase (Life Technologies, Gaithersburg, Md). E2F-1 sequences were prepared by polymerase chain reaction using rTth DNA polymerase XL (Perkin-Elmer, Norwalk, Conn) along with the following primers: sense primer 5Ј-CGTGAGCGTCATGGC-CTTG-3Ј and antisense primer 5Ј-CCAAGCCCTGTCA-GAAATCCA-3Ј. (Primers were designed according to the E2F-1 sequence obtained from GenBank Accession Number M96577). The polymerase chain reaction-amplified fragment was cloned into pCR-Script vector, and positive clones were identified and sequenced. Double-stranded DNA sequencing was performed in our institutional sequencing core facility.
Recombinant adenovirus construction and infection
The recombinant E2F-1 adenovirus (Ad5CMV-E2F-1) contains the human cytomegalovirus (CMV) promoter, E2F-1 cDNA, and bovine growth hormone polyadenylation signal in a mini-gene cassette inserted into the E1-deleted region of modified adenovirus type 5 (Ad5). The replication-defective adenovirus Ad5⌬E1 (provided by Dr. Bingliang Fang, M.D. Anderson Cancer Center, Houston, Tex) was generated by cotransfecting the pXCJL-1 and pJM 17 plasmids (kindly provided by Dr. Frank Graham, McMaster University, Hamilton, Canada) 17 into 293 cells. Viral stocks were propagated in 293 cells. Cells were harvested at 36 -40 hours postinfection, pelleted, resuspended in phosphate-buffered saline (PBS), and lysed; cell debris was removed by subjection to CsCl gradient purification. Viral titers were determined by immunofluorescent staining. 18 The titer of Ad5CMVE2F-1 is 1 ϫ 10 11 infectious units (IU)/mL, and Ad5⌬E1 is 2 ϫ 10 11 IU/mL. Concentrated virus was dialyzed, aliquoted, and stored at Ϫ80°C. The infection was performed by addition of the virus in DMEM/Ham's F12 medium and 2% FBS to cell monolayers. The cells were then incubated at 37°C for 60 minutes with constant agitation, complete medium (DMEM/Ham's F12/ 10% FBS) was added, and the cells were incubated at 37°C for the desired length of time.
Western blot analysis
Total cell lysates were prepared by sonicating the cells at 24 hours postinfection in radioimmunoprecipitation assay buffer (150 mM NaCl, 1.0% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and 50 mM tris(hydroxymethyl)aminomethane, pH 8.0) for 5 seconds. A total of 50 g of protein from samples was subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred to a Hybond-enhanced chemiluminescence membrane (Amersham, Arlington Heights, Ill). The membrane was blocked with Blotto/Tween (5% nonfat dry milk, 0.2% Tween-20, and 0.02% sodium azide in PBS) and probed mouse anti-human E2F-1 monoclonal KH95 (Santa Cruz Biotechnology, Santa Cruz, Calif) as well as the secondary antibody, horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (Boehringer Mannheim, Indianapolis, Ind). The membrane was processed and developed as suggested by the manufacturer.
Chloramphenicol acetyltransferase (CAT) assays E2F-1 transactivation activity was measured using CAT activity as expressed from the transfection of pRb (p-194)-CAT 19 and virus infection. The reporter plasmid (10 g) and a CMV-␤-galactosidase (␤-gal) standard (5 g) were transfected into cells by calcium-phosphate precipitation for 24 hours and subsequently infected with E2F-1 adenovirus and a control adenovirus. Cells were harvested at 24 hours postinfection and processed for CAT activity. 15 The amount of cell extracts used in CAT assays was normalized with the ␤-gal protein level.
Gel-retardation assays
Gel-retardation assays were performed as described previously 15 with a minor modification. A total of 5-20 g of cell extract was used directly in a binding buffer containing 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.6), 50 mM NaCl, 1 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.1% Nonidet P-40, and 5% glycerol, to which 0.1 ng of 32 P-labeled probe and 500 ng of poly(dI-dC) was added. The reaction products were separated on a 5% polyacrylamide gel run in 0.25ϫ Tris-borate-EDTA at 4°C.
In vitro cell growth assay
Cells were plated in triplicate at 2 ϫ 10 4 cells/well with 3 mL of medium in six-well plates. Cells were infected either with Ad5CMV-E2F-1 adenovirus or with a replication-deficient adenovirus (Ad5⌬E1) as a control. Cells were harvested every 2 days and counted; their viability was determined by trypan blue exclusion.
Ex vivo animal experiments
The effect of Ad5CMV-E2F-1 on tumor growth was determined in nude mice in a defined, pathogen-free environment. Experiments were reviewed and approved by institutional committees for both animal care and use and for recombinant DNA research. Briefly, cells were infected with the Ad5CMV-E2F-1 adenovirus and the Ad5⌬E1 replication-defective virus for 24 hours. Cells were then harvested for subsequent injection into animals. Following an induction of acetopromazine/ ketamine anesthesia, each animal received three subcutaneous (s.c.) injections of Tu-138 cells at different sites at a concentration of 4 ϫ 10 6 cells/100 L of complete media. The Ad5CMV-E2F-1-infected cells were injected into the left posterior flank of each animal. The right posterior flank received mock-infected cells. Cells infected with replicationdefective virus (Ad5⌬E1) were injected into the right anterior flank of each animal. Animals were sacrificed after 28 days, and excised tumors were measured three-dimensionally with microcalipers to determine tumor volume using following formula: V ϭ length ϫ (width)2 ϫ 0.5. A nonparametric Friedman's two-way analysis of variance test was used to test the statistical significance of the difference between the means of samples.
In vivo analysis of apoptosis
The effect of Ad5CMV-E2F-1 on established s.c. tumor nodules was determined in nude mice in a defined pathogen-free environment. Briefly, following induction of acetopromazine/ ketamine anesthesia, 5 ϫ 10 6 Tu-138 cells in 150 L of complete media were seeded s.c. into three flanks of animals as described in the ex vivo experiment. After tumor nodules had developed, the animals were reanesthetized and injected with 10 9 IU/100 L of Ad5CMV-E2F-1 in the left posterior flank, replication-defective virus (Ad5⌬E1) in the right anterior flank, and Ad5CMV-p53 in the right posterior flank. Animals developed s.c. visual and palpable nodules before viral injection. Animals were sacrificed at 72 hours after adenoviral vector injections, and the tumor sections were prepared for the detection of apoptotic cells using in situ end-labeling analyses.
DNA fragmentation analysis
Following infection with AdCMV-E2F-1 and a replicationdefective adenovirus control at various time intervals, cells were harvested, resuspended in 300 L of PBS with an addition of 3 mL of extraction buffer (10 mM Tris (pH 8.0), 0.1 M EDTA, 20 g/mL RNase, and 0.5% SDS), and incubated at 37°C for 1-2 hours. At the end of incubation, proteinase K was added to a final concentration of 100 g/mL, and the solution was placed in a 50°C water bath for Ն3 hours. DNA was extracted once with an equal volume of 0.5 M Tris (pH 8.0) saturated phenol, and the extraction was subsequently repeated with phenol/chloroform. Precipitated DNA was analyzed in a 1.5% agarose gel.
Terminal deoxynucleotidyl transferase (TdT)-mediated deoxy deoxyuridine triphosphate (dUTP)-biotin nick end-labeling (TUNEL) assays
Briefly, after fixation and washing, cells were resuspended in 50 L of TdT buffer containing 0.2 M sodium cacodylate (pH 7.0), 2.5 mM Tris-HCl, 2.5 mM C 0 Cl 2 (Sigma, St. Louis, Mo), 0.1 mM dithiothreitol (Sigma), 0.25 mg/mL bovine serum albumin (Sigma), 5 U of terminal transferase (Boehringer Mannheim), and 0.5 nmol of biotin-16-dUTP along with deoxyadenosine triphosphate, deoxyguanosine triphosphate, and deoxycytosine triphosphate at a concentration of 20 M. Controls were prepared by incubating a separate aliquot of each test sample without dUTP. The cells were incubated in the solution at 37°C for 30 minutes, rinsed in PBS, and resuspended in 100 L of fluorescein isothiocyanate, the staining solution containing 4 ϫ standard saline citrate, 0.1% Triton X-100, and 2.5 g/mL fluoresceinated avidin (Vector Labs, Burlingame, Calif). Tubes were incubated for 30 minutes in the dark at room temperature. Cells were rinsed in PBS with 0.1% Triton X-100 and resuspended in 0.5 mL of PBS containing propidium iodide (PI) (5 g/mL) and 70 L (1 mg/mL) of RNase. Tubes were incubated in the dark on ice for 30 minutes before flow cytometric analysis.
In situ end-labeling analyses
The procedure was performed as described previously. 8 Briefly, paraffin sections were dewaxed in xylene for 5 minutes three times each, and progressively hydrated by immersing the slides for 3 minutes each in 100%, 90%, 70%, and 30% ethanol solutions. Endogenous peroxidase was inactivated by immersing the slides for 20 minutes in 0.75% H 2 O 2 vol/vol in 100% methonal. After the slides had been washed in PBS, sections were digested with 0.1% pepsin (Fisher Scientific, Houston, Tex) wt/vol in 0.1 N HCl for 5 minutes at 37°C and washed extensively in PBS. Sections were then incubated in a moist chamber at 37°C for 1 hour with an end-labeling cocktail that included the following: 0.5 U/L TdT, 0.06 mM biotinylated dUTP, 10 L of 5 ϫ TdT buffer, and Յ50 L of doubledistilled water. The reaction was terminated by immersing the slides in a buffer containing 300 mM NaCl and 30 mM sodium citrate in double-distilled water. After the slides had been washed in PBS, sections were incubated with horseradish peroxide-conjugated avidin for 1 hour at 37°C in a moist chamber. Staining was developed using 3,3Ј-diaminobenzidine, and sections were counterstained with methyl green. 8 Recent studies have shown that an enforced expression of E2F-1 in quiescent fibroblasts induces apoptosis. 15 We constructed a recombinant E2F-1 adenovirus to investigate whether E2F-1 could also promote apoptosis in proliferating tumor cells. Two SCCHN cell lines (Tu-138 and Tu-167) were chosen for use in our initial study. Tu-138 not only harbored a mutated p53 gene but also expressed an undetectable level of Rb protein, suggesting Rb mutation. Tu-167 contained a mutated p53 gene and expressed high levels of Rb protein (our unpublished data). We have demonstrated previously that a 60% transduction efficiency can be achieved in SCCHN cells using 100 multiplicity of infection of adenovirus. 16 Following infection with 100 multiplicity of infection of Ad5CMV-E2F-1, both cell lines expressed elevated levels of the 60-kDa E2F-1 protein (Fig  1, lanes 3 and 6) ; in control experiments, only a basal or undetectable level of E2F-1 protein was noted (Fig 1,  lanes 1, 2, 4 , and 5). The functional activity of the transduced E2F-1 gene was assessed by gel shift and CAT assays. A gel-retardation assay was performed to test the binding affinity of E2F-1 protein to an oligonucleotide containing an E2F-1 binding site. In cells infected with Ad5CMV-E2F-1, multiple factors that bound to the E2F-1 oligonucleotide sequences were detected (Fig 2A, lanes 4 and 9) . Binding specificity was demonstrated by incubating either with 200-fold excess of cold E2F-1 oligonucleotide (Fig 2A, lanes 5 and 10) or with the same concentration of mutated E2F-1 oligonucleotide (Fig 2A, lanes 6 and 11) . One unidentified high-molecular weight band was detected in all experiments with the exception of the mock-infected controls. This could be the result of nonspecific binding of adenoviral protein(s) in the infected cells. Neither wt nor mutated E2F-1 oligonucleotide could abolish such interactions. A CAT assay was also performed to evaluate the transactivation function of E2F-1 protein in the adenoviral-infected cells. A reporter construct, pRb (p-194)-CAT, 19 that contained a single E2F-1 binding site along with a ␤-gal standard was transfected into cells 24 hours before the E2F-1 adenoviral infection. At 24 hours postinfection, cell extracts were prepared and assayed for CAT enzyme activity. The E2F-1 viralinfected cells showed high levels of CAT activity, indicating that the transduced E2F-1 gene possesses functional activity.
RESULTS
Expression of
Effect of elevated levels of E2F-1 protein on SCCHN cell growth both in vitro and in an ex vivo animal model The biological activity of the exogenous E2F-1 protein was determined in an in vitro growth assay as well as in an ex vivo animal model. An assessment of standard in vitro growth rates 16 was performed on both Tu-138 and Tu-167 cell lines. As shown in Figure 3A , both cell lines exhibited a loss of viability upon AdCMV-E2F-1 infection. These two cell lines both contain the mutated p53 gene while possessing a different status of the Rb gene. The suppressive effect of Tu-167 cells by E2F-1 protein was not as profound as the effect of Tu-138 cells. This could be attributable to the high levels of Rb protein in Tu-167 cells. Because E2F-1 activity is partly modulated by complex formation with the Rb protein, it is possible that the Rb/E2F-1 complex is less effective on growth suppression in Tu-167 cells. The growth assay was also performed on another cell line, 686LN, which contains a genotypic wt p53 gene. A similar growth-suppressive effect was observed following Ad5CMV-E2F-1 infection (Fig 3A) .
In view of the growth-suppressive effect of the E2F-1 protein on all of the cell lines tested in vitro, we sought to investigate the effect of E2F-1 on the tumorigenicity of cells in animals. An ex vivo animal model was used to test the tumorigenicity of cells following Ad5CMV-E2F-1 infection. Mock-infected cells, Ad5CMV-E2F-1-infected cells, and Ad5⌬E1-infected cells were implanted s.c. at three sites in athymic nude mice. Seven animals were used to test the cell line Tu-138. At 28 days after tumor cell seeding, sizable tumors were apparent on two sites of animals that received mock-infected and control viral-infected cells. The lack of tumor formation was significant in the right posterior flanks of the animals that received Ad5CMV-E2F-1-infected cells (P Ͻ .05). Figure 3B shows representative recipients of Tu-138 cells. The tumor volumes derived in the Tu-138 cell studies are shown in Table 1 . The data indicate that an overexpression of E2F-1 in SCCHN cells results in growth suppression, and that Ad5CMV-E2F-1-infected cells lose their ability to form tumors in nude mice.
Induction of programmed cell death by E2F-1 overexpression
The morphological changes of cells infected with Ad5CMV-E2F-1 suggested the occurrence of apoptosis. A DNA fragmentation analysis was performed to confirm the notion that the cells had undergone apoptosis following Ad5CMV-E2F-1 infection. Chromosomal DNA extracted from the viable cells following replication-defective or Ad5CMV-E2F-1 infection was subjected to agarose gel electrophoresis. The DNA fragments of ϳ200 base pairs and their multiples appeared in both cell lines. The fragmented DNA appeared earlier in Tu-138 cells than in Tu-167 cells following Ad5CMV-E2F-1 infection. This finding is consistent with other analyses, indicating that Tu-138 cells are more sensitive to E2F-1-induced apoptosis than are Tu-167 cells. Cell-cycle analysis was performed in conjunction with the TUNEL assay to assess the cell-cycle distribution of Ad5CMV-E2F-1-infected cells and to demonstrate apoptosis in these infected cells. The results of these analyses are summarized in Table 2 . The cell-cycle analyses showed that a high percentage of Ad5CMV-E2F-1 infected cells in the S phase, suggesting that the transduced E2F-1 gene does indeed force cell cycling at the S phase. A delay in response to the apoptotic induction by E2F-1 was noted in Tu-167 cells (i.e., 20% of apoptosis at 72 hours postinfection) compared with Tu-138 cells (i.e., 47% of apoptosis at 48 hours postinfection); this delay correlates well with the in vitro growth curve. The number of apoptotic cells increased proportionally with the duration of E2F-1 adenovirus incubation. Figure 4B shows the PI staining of Tu-167 cells before the TUNEL analysis as well as the fluorescence staining of apoptotic Tu-167 cells after TUNEL analysis. Figure 4A represents DNA staining of mock-infected cells with PI. Figure 4B shows DNA staining of Tu-167 cells at 72 hours following Ad5CMV-E2F-1 infection. Figure 4C shows mock-infected cells after TUNEL analysis. Figure  4D shows the high intensity of fluorescent staining of Ad5CMV-E2F-1-infected cells after TUNEL analysis, indicating apoptosis induction following overexpression of the E2F-1 protein.
To demonstrate the ability of E2F-1 to induce apoptosis in vivo, Ad5(⌬E1), Ad5CMV-p53, and Ad5CMV-E2F-1 were intratumorally (i.t.) injected into tumor-bearing animals for 72 hours in previously described three-flap models. 20 Tumor sections were prepared, and in situ end-labeling was performed for the identification of apoptotic cells. No staining was observed in the tissue sections isolated from Tu-138-bearing animals ( Fig 5A, hematoxylin and eosin staining of tumor) that had received replication-defective adenovirus treatment as a control (Fig 5B) . However, tissue sections isolated from tumor-bearing mice treated with Ad5CMV-E2F-1 showed positive staining (Fig 5C) . The wt p53 adenovirus, which has been demonstrated to induce apoptosis in vivo, 20 was used as a positive control (Fig 5D) . These data indicate that E2F-1 is capable of inducing apoptosis in vivo.
DISCUSSION
Homeostatic control of cell populations in multicellular organisms is regulated by balancing the rate of cell proliferation with the rate of cell death. Apoptosis, or programmed cell death, is a highly conserved genetic mechanism by which cells execute their own destruction in response to the changing environment. Therefore, it is not unreasonable to suggest that the cancer may occur in part because of dysregulated cell death. Although the mechanism of apoptosis is conserved throughout evolution from nematodes to humans, the process is far more complicated in mammals. Advances in the field of apoptosis research have shed some light on the molecular basis of the apoptotic process.
A handful of apoptosis-inducing genes has been identified, including Bax, 10 c-Myc, 21 adenoviral E1A, 22 and p53. [5] [6] [7] [8] Recent studies 15 have demonstrated that overexpression of E2F-1 in a quiescent fibroblast cell line could induce apoptosis in a p53-dependent manner. A recombinant E2F-1 adenovirus was generated to test whether an overexpression of E2F-1 in proliferating SCCHN tumor cells would also lead to apoptosis. High levels of E2F-1 protein were detected in cells following E2F-1 adenoviral infection. A gel-retardation assay revealed at least two high-mobility bands in Ad5CMV-E2F-1-infected cells; these bands could be competed away with excess cold wt E2F-1 oligonucleotide, suggesting that the binding of induced E2F-1 protein is rather specific. These data suggest that the factor(s) associated with E2F-1 protein were present in Ad5CMV-E2F-1-infected cells. Whether DP-1, 13 cyclin A, 23 or the heterodimeric of the DP-1/E2F-1 complex with underphosphorylated species of pRb 24 contributed to these bands is currently being investigated. The functionality of exogenous E2F-1 protein was also confirmed via CAT assay. In the assay, the E2F-1 protein could transactivate a CAT reporter construct driven by an Rb promoter containing one E2F-1 binding site.
The biological activity of the exogenous E2F-1 protein was further examined in an in vitro growth assay, an ex vivo tumorigenicity assay, and an in situ end-labeling assay following i.t. adenoviral injection. The growth rates of cell lines Tu-138 (Rb(Ϫ)/p53(mutated)) and Tu-167 (Rb(ϩ)/p53(mutated)) were suppressed following E2F-1 adenoviral infection. The SCCHN cell lines infected with recombinant E2F-1 adenovirus clearly showed apoptosis. The biological effect of E2F-1 was further demonstrated in animals. The E2F-1 protein also induced apoptosis in tumors via i.t. administration of adenoviral vector. The activity is comparable with that of an earlier described p53 adenoviral vector. 8 Interestingly, the initiation of apoptosis in Tu-167 cells was delayed compared with that of Tu-138 cells, as noted in in vitro growth curve and TUNEL assays. This difference could conceivably be attributable to the ability of high levels of the Rb protein in Tu-167 cells to compensate for the effect exerted by E2F-1. However, the markedly elevated levels of E2F-1 protein in the infected cells eventually overcome such a balance by the Rb protein and ultimately lead to cell death. Moreover, our data suggest that the status of the p53 gene does not affect the result of apoptosis following E2F-1 adenoviral infection. These notions are supported in a recent article by Hsieh et al, 25 in which they demonstrate that E2F-1 can induce apoptosis in Saos-2 cells in p53-independent manner. Apoptosis induction by E2F-1 was partially inhibited by the Rb protein through direct interaction.
An ex vivo animal model was used to examine the tumorigenicity of cells following E2F-1 adenoviral infection. Tumor formation was inhibited in all sites that received Ad5CMV-E2F-1-infected cells. This approach is different from that used with the in vivo model, which we have described previously, 4 in that the tumor nodules were developed before the molecular intervention.
The role of p53 in activating apoptosis on E2F-1 overexpression has been documented in a rat embryonic fibroblast cell line. 15 However, reports also suggested the possible existence of a p53-independent pathway. Our data suggest that E2F-1-induced apoptosis in SCCHN cells occurs through a p53-independent pathway. This observation can be extended to breast cancer 26 and glioma cell lines. The discrepancy could possibly exist because the mechanism of apoptotic induction by E2F-1 in rat fibroblast cells is regulated differently than in human tumor cells. Alternatively, the cell lines used in our study may contain silence mutations and therefore still possess the residual activity of their wt counterparts. Lastly, it is feasible that the response to the overexpression of E2F-1 may be cell-type specific.
Recently, E2F-1 was shown to possess the functions of a tumor suppressor gene in a knockout mouse model. 27, 28 The manifestation of transcription factor and tumor suppressor activities by E2F-1 is reminiscent of the function of the p53 gene. Whether the mechanism(s) in apoptosis induction that are exerted by these two genes share any similarity remains to be elucidated.
In summary, we have demonstrated here that the †Ad5CMV-E2F-1 is abbreviated as E2F-1. ‡⌬E1 is an abbreviation for Ad5⌬E1. overexpression of E2F-1 in SCCHN cells induced apoptosis despite their different profiles of various genes. Contemporary surgery, radiation therapy, and chemotherapy have altered some approaches in the management of head and neck cancer but have not affected survival. Gene transfer strategies now provide us with the ability to translate recent advances in molecular understanding into the regulation of malignancies. 29 Strategies for selectively inducing apoptosis in solid tumors using E2F-1 are an attractive approach for molecular therapy and require further investigation. Figure 5 . In vivo analysis for apoptosis by in situ end-labeling. Established tumors in animals were injected with Ad5⌬E1, Ad5CMV-E2F-1, and p53 adenovirus for 3 days before tissue sections were prepared. A represents the hematoxylin and eosin staining of tumors (magnification is ϫ40). B shows the negative staining of tumors injected with Ad5⌬E1 (magnification is ϫ40). C exhibits positive staining for apoptosis of the tumor that received Ad5CMV-E2F-1 (magnification is ϫ100). D reveals a slightly higher number of positively stained tumors that received the p53 adenovirus (magnification is ϫ100).
